Literature DB >> 22241571

Lung function decline from adolescence to young adulthood in cystic fibrosis.

Stacy L Vandenbranden1, Ann McMullen, Michael S Schechter, David J Pasta, Rory L Michaelis, Michael W Konstan, Jeffrey S Wagener, Wayne J Morgan, Susanna A McColley.   

Abstract

BACKGROUND: Despite improving survival in cystic fibrosis (CF) patients, there is a mortality peak in early adulthood. Defining risk factors that predict significant worsening of lung disease in young adulthood may identify opportunities to improve outcomes in adults.
METHODS: We identified 4,680 patients in the Epidemiologic Study of Cystic Fibrosis 1994-2005 with data in both adolescence (age 14.0-17.4 years) and young adulthood (age 18.5-22.0 years) and analyzed 2,267 who had ≥5 encounters and ≥5 measurements of forced expiratory volume in 1 second (FEV(1) ) spanning ≥1 year during both adolescence and young adulthood, and ≥1 encounter with weight and height and ≥1 FEV(1) measurement age 17.5-18.5 years. We compared the annualized rates of decline in FEV(1) during adolescence and young adulthood stratified by best FEV(1) around age 18. Logistic regression was used to identify risk factors associated with substantial decline (>20 points) in FEV(1) % predicted in young adulthood.
RESULTS: Annual rate of decline was greater in young adulthood than in adolescence. Risk factors for substantial decline included slower rate of FEV(1) decline, greater FEV(1) variability, faster body mass index (BMI) decline, male sex, chronic inhaled antibiotics, Haemophilus influenzae detection, and absence of multidrug-resistant Pseudomonas aeruginosa in adolescence, and lower than expected FEV(1) and BMI around age 18.
CONCLUSIONS: Decline in lung function accelerates in young adults with CF, especially in those with early stage lung disease. Adolescents at risk for substantial decline in lung function in young adulthood have higher FEV(1) and worse nutritional status, among other identifiable risk factors.
Copyright © 2011 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22241571      PMCID: PMC4219484          DOI: 10.1002/ppul.21526

Source DB:  PubMed          Journal:  Pediatr Pulmonol        ISSN: 1099-0496


  21 in total

1.  Is there still a gender gap in cystic fibrosis?

Authors:  Nisha Verma; Andrew Bush; Roger Buchdahl
Journal:  Chest       Date:  2005-10       Impact factor: 9.410

2.  Risk factors for rate of decline in forced expiratory volume in one second in children and adolescents with cystic fibrosis.

Authors:  Michael W Konstan; Wayne J Morgan; Steven M Butler; David J Pasta; Marcia L Craib; Stefanie J Silva; Dennis C Stokes; Mary Ellen B Wohl; Jeffrey S Wagener; Warren E Regelmann; Charles A Johnson
Journal:  J Pediatr       Date:  2007-06-22       Impact factor: 4.406

3.  Year-to-year changes in lung function in individuals with cystic fibrosis.

Authors:  Theodore G Liou; Eric P Elkin; David J Pasta; Joan R Jacobs; Michael W Konstan; Wayne J Morgan; Jeffrey S Wagener
Journal:  J Cyst Fibros       Date:  2010-05-14       Impact factor: 5.482

4.  Predictive 5-year survivorship model of cystic fibrosis.

Authors:  T G Liou; F R Adler; S C Fitzsimmons; B C Cahill; J R Hibbs; B C Marshall
Journal:  Am J Epidemiol       Date:  2001-02-15       Impact factor: 4.897

5.  Wasting as an independent predictor of mortality in patients with cystic fibrosis.

Authors:  R Sharma; V G Florea; A P Bolger; W Doehner; N D Florea; A J Coats; M E Hodson; S D Anker; M Y Henein
Journal:  Thorax       Date:  2001-10       Impact factor: 9.139

6.  Haemophilus influenzae forms biofilms on airway epithelia: implications in cystic fibrosis.

Authors:  Timothy D Starner; Niu Zhang; Gunhee Kim; Michael A Apicella; Paul B McCray
Journal:  Am J Respir Crit Care Med       Date:  2006-05-04       Impact factor: 21.405

7.  Clinical use of dornase alpha is associated with a slower rate of FEV1 decline in cystic fibrosis.

Authors:  Michael W Konstan; Jeffrey S Wagener; David J Pasta; Stefanie J Millar; Joan R Jacobs; Ashley Yegin; Wayne J Morgan
Journal:  Pediatr Pulmonol       Date:  2011-03-24

8.  Relationship between inhaled corticosteroid therapy and rate of lung function decline in children with cystic fibrosis.

Authors:  Clement L Ren; David J Pasta; Lawrence Rasouliyan; Jeffrey S Wagener; Michael W Konstan; Wayne J Morgan
Journal:  J Pediatr       Date:  2008-08-30       Impact factor: 4.406

9.  Transition and transfer of patients who have cystic fibrosis to adult care.

Authors:  H Worth Parker
Journal:  Clin Chest Med       Date:  2007-06       Impact factor: 2.878

10.  Cystic fibrosis-related diabetes: current trends in prevalence, incidence, and mortality.

Authors:  Antoinette Moran; Jordan Dunitz; Brandon Nathan; Asad Saeed; Bonnie Holme; William Thomas
Journal:  Diabetes Care       Date:  2009-06-19       Impact factor: 19.112

View more
  37 in total

1.  Inhaled tobramycin effectively reduces FEV1 decline in cystic fibrosis. An instrumental variables analysis.

Authors:  Rhonda D VanDyke; Gary L McPhail; Bin Huang; Matthew C Fenchel; Raouf S Amin; Adam C Carle; Barb A Chini; Michael Seid
Journal:  Ann Am Thorac Soc       Date:  2013-06

2.  Joint hierarchical Gaussian process model with application to personalized prediction in medical monitoring.

Authors:  Leo L Duan; Xia Wang; John P Clancy; Rhonda D Szczesniak
Journal:  Stat (Int Stat Inst)       Date:  2018-03-04

3.  Early Detection of Rapid Cystic Fibrosis Disease Progression Tailored to Point of Care: A Proof-of-Principle Study.

Authors:  Rhonda Szczesniak; Cole Brokamp; Weiji Su; Gary L McPhail; John Pestian; John P Clancy
Journal:  Health Innov Point Care Conf       Date:  2017-12-21

4.  Psychological predictors of nutritional adherence in adolescents with cystic fibrosis.

Authors:  Adrienne P Borschuk; Stephanie S Filigno; Lisa Opipari-Arrigan; James Peugh; Lori J Stark
Journal:  Clin Nutr ESPEN       Date:  2019-06-19

Review 5.  Protein is an important but undervalued macronutrient in the nutritional care of patients with cystic fibrosis.

Authors:  Mariëlle P K J Engelen; Gulnur Com; Nicolaas E P Deutz
Journal:  Curr Opin Clin Nutr Metab Care       Date:  2014-11       Impact factor: 4.294

6.  Phenotypes of Rapid Cystic Fibrosis Lung Disease Progression during Adolescence and Young Adulthood.

Authors:  Rhonda D Szczesniak; Dan Li; Weiji Su; Cole Brokamp; John Pestian; Michael Seid; John P Clancy
Journal:  Am J Respir Crit Care Med       Date:  2017-08-15       Impact factor: 21.405

7.  Risk factors for onset of persistent respiratory symptoms in children with cystic fibrosis.

Authors:  Susanna A McColley; Clement L Ren; Michael S Schechter; Warren E Regelmann; David J Pasta; Michael W Konstan
Journal:  Pediatr Pulmonol       Date:  2012-02-22

8.  Shared parameter models for joint analysis of longitudinal and survival data with left truncation due to delayed entry - Applications to cystic fibrosis.

Authors:  Mark D Schluchter; Annalisa V Piccorelli
Journal:  Stat Methods Med Res       Date:  2018-04-04       Impact factor: 3.021

9.  Effects of puberty on cystic fibrosis related pulmonary exacerbations in women versus men.

Authors:  Shelby Sutton; Daniel Rosenbluth; Deepa Raghavan; Jie Zheng; Raksha Jain
Journal:  Pediatr Pulmonol       Date:  2013-03-04

Review 10.  Influences of environmental exposures on individuals living with cystic fibrosis.

Authors:  Rhonda Szczesniak; Jessica L Rice; Cole Brokamp; Patrick Ryan; Teresa Pestian; Yizhao Ni; Eleni-Rosalina Andrinopoulou; Ruth H Keogh; Emrah Gecili; Rui Huang; John P Clancy; Joseph M Collaco
Journal:  Expert Rev Respir Med       Date:  2020-04-26       Impact factor: 3.772

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.